At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Sitravatinib +1 moredrug
Likely dose
Nivolumab 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Sitravatinib and Nivolumab for Clear Cell Renal Cell Carcinoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionApr 2020
Study CompletionMay 2023
TodayJul 2026
First PostedSep 21, 2018
Enrollment StartOct 10, 2018
Primary CompletionApr 27, 2020
Study CompletionMay 18, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.8 years ago
Interventions
Sitravatinibdrug
Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
Nivolumabdrug
Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.